Choose Your Own Antibiotic/Adventure Gram-Positive Style
|
|
- Timothy Holmes
- 5 years ago
- Views:
Transcription
1 Disclosures Consultant for Cubist Pharmaceuticals, Inc Research support from Forest Laboratories Choose Your Own Antibiotic/Adventure Gram-Positive Style I have never seen Star Wars (But I m a big fan of Space Balls, the movie) Monica V. Mahoney, PharmD, BCPS (AQ ID) Objectives At the end of the presentation, the participant should be able to: 1. Evaluate the literature for the newly approved Grampositive medications dalbavancin, oritavancin and tedizolid 2. Compare/contrast the newer agents against older Grampositive antimicrobials 3. Given a patient with a Gram-positive infection, recommend appropriate therapy Dalbavancin Lipoglycopeptide antibiotic 1000 mg IV x 1, then 500 mg IV 7 days later Red man s syndrome, nausea, diarrhea, pruritis $4500 +/- Dalvance Prescribing Information Dalbavancin in Skin/Soft Tissue DISCOVER Dalbavancin in Skin/Soft Tissue cont.. DAL VAN +/- LZD 1000 mg 500 mg Placebo IV q12h +/- PO placebo q12h VAN 1000 mg (15 mg/kg) IV q12h LZD 600 mg PO q12h endpoint End of therapy n=659 n= Shortterm f/u 70 Longterm f/u Boucher. NEJM 2014;370: Demographics DAL (n=659) VAN / LZD (n=653) Age: mean (range) 48.9 (18-85) years 50.3 (18-84) years Male: no (%) 393 (59.6) 374 (57.3) Diabetes: no (%) 78 (11.8) 92 (14.1) IVDU: no (%) 94 (14.3) 107 (16.4) Infection Type: no (%) Major abscess 162 (24.6) 173 (26.5) Cellulitis 354 (53.7) 349 (53.4) Wound/SSI 142 (21.5) 131 (20.1) Febrile ( 38 C) 549/649 (84.6) 552/649 (85.0) WBC >12,000 cells/m 3 247/627 (39.4) 250/621 (40.3) Infection area: median (range) 324 ( ) cm ( ) cm 2 Boucher. NEJM 2014;370:
2 Dalbavancin in Skin/Soft Tissue cont.. Results DAL VAN / LZD Success rate at 48-72h 525/659 (79.7%) 521/653 (79.8%) Success rate at EOT 517/570 (90.7%) 502/545 (92.1%) Cellulitis At 48-72h 281/354 (79.4%) 269/349 (77.1%) At EOT 294/324 (90.7%) 276/301 (91.7%) Major Abscess At 48-72h 133/163 (81.6%) 149/173 (86.1%) At EOT 125/133 (94.0%) 133/139 (95.7%) Wound/SSI At 48-72h 111/142 (78.2%) 103/131 (78.6%) At EOT 98/113 (86.7%) 93/105 (88.6%) MRSA (EOT) 72/74 (97.3%) 49/50 (98.0%) Dalbavancin in Skin/Soft Tissue cont.. Adverse Events: Nausea (2.5%), diarrhea (0.8%), pruritis (0.6%) Median duration: 4.0 days (DAL) vs. 3.0 days (VAN/LZD) Conclusion: Once weekly DAL is not inferior to twice daily VAN/LZD for the treatment of acute bacterial skin and skin-structure infections (ABSSSI) Boucher. NEJM 2014;370: Boucher. NEJM 2014;370: Dalbavancin Future Directions? Single Dose Dalbavnacin: Ph3, DB, RCT: DAL 1500 mg vs. DAL 1000 mg / 500 mg for ABSSSI (NCT ) Pediatrics: Ph1, open-label, ages ys, bacteremia (NCT ) Ph1, open-label, ages 3 mos-11 yrs (NCT ) Community Acquired Pneumonia: Ph3, DB, RCT vs. linezolid (NCT ) Osteomyelitis: Ph3, DB, RCT vs. cefaz/oxa/naf/van. Ages 2-17 yrs. (NCT ) Oritavancin Glycopeptide antibiotic 1200 mg IV x 1 Headache, nausea, vomiting, abscess, diarrhea $ Orbactiv Prescribing Information Oritavancin in Skin/Soft Tissue SOLO Oritavancin in Skin/Soft Tissue cont.. ORI VAN 1200 mg Placebo IV q12h 1000 mg (15 mg/kg) IV q12h endpoint End of therapy n=978 n=981 Post-therapy evaluation Corey et al. N Engl J Med. 2014;370: Corey et al. Clin Infect Dis 2014; doi: /cid/ciu778 Demographics ORI (n=978) VAN (n=981) Age: median 45.6 years ~ 45 years Male: no (%) 639 (65.3) 644 (65.6) Diabetes: no (%) 139 (14.2) 140 (14.3) IVDU: no (%) Not reported Not reported Infection Type: no (%) Major abscess 308 (31.5) 300 (30.6) Cellulitis 387 (39.6) 400 (40.8) Wound/SSI 283 (28.9) 281 (28.6) Febrile ( 38 C) 186/976 (19.1) 185/979 (19.0) WBC >12,000 cells/m 3 216/887 (24.4) 210/879 (23.9) Infection area: median (range) ( ) cm 2 ~250 ( ) cm 2 Corey et al. N Engl J Med. 2014;370: Corey et al. Clin Infect Dis 2014; doi: /cid/ciu778 2
3 Oritavancin in Skin/Soft Tissue cont.. Results ORI (n=978) VAN (n=981) Success rate at 48-72h 794 (81.2%) 794 (80.9%) Success rate at PTE 794 (81.2%) 787 (80.2%) Cellulitis At 48-72h 294/387 (76.0%) 302/400 (75.5%) Major Abscess At 48-72h 251/308 (81.5%) 253/300 (84.3%) Wound/SSI At 48-72h 249/283 (88.0%) 239/281 (85.1%) MRSA (EOT) 166/204 (81.4%) 162/201 (80.6%) Oritavancin in Skin/Soft Tissue cont.. Adverse Events: Nausea (9.9%), headache (7.1%), vomiting (4.6%), abscess (3.8%0, diarrhea (3.7%) Average onset: SOLO I: 1.2 days; duration: 2.4 days SOLO II: all within 1-9 days of medication start Conclusion: Single dose IV ORI was non-inferior compared to IV VAN x 7-10 days in the treatment of ABSSSI Corey et al. N Engl J Med. 2014;370: Corey et al. Clin Infect Dis 2014; doi: /cid/ciu778 Orbactiv Prescribing Information Oritavancin Future Directions? Pediatrics: Ph1, open label, dose-finding study in pediatrics Single ORI infusion for confirmed/suspected bacteremia in patients < 18 years (NCT ) Tedizolid Oxazolidinone antibiotic 200 mg IV/PO q24h Nausea, vomiting, diarrhea, headache, dizziness $1400 *6 day course Sivextro Prescribing Information Tedizolid in Skin/Soft Tissue ESTABLISH Tedizolid in Skin/Soft Tissue cont.. TZD LZD 200 mg PO/IV q24h Placebo PO/IV q12h 600 mg PO/IV q12h Placebo PO/IV q24h 1 endpoint Placebo PO q24h End of therapy n=664 n= Post-therapy evaluation Prokocimer. JAMA 2013;309: Moran. Lancet Infect Dis. 2014;14: Demographics TZD (n=664) LZD (n=669) Age: mean (I and II) 43.6 and 46 years 43.1 and 46 years Male: no (%) 429 (64.6) 412 (61.6) Diabetes: no (%) (II only) 32/332 (10.0) 41/334 (12.0) IVDU: no (%) 183 (27.6) 206 (30.8) Infection Type: no (%) Major abscess 168 (25.3) 166 (24.8) Cellulitis 301 (45.3) 307 (45.9) Wound/SSI 195 (29.4) 196 (29.3) Febrile ( 38 C) 159 (23.9) 160 (23.9) WBC >10,000 cells/m (47.6) 284 (42.5) Infection area: median (range) (I only) ( ) cm ( ) cm 2 Prokocimer. JAMA 2013;309: Moran. Lancet Infect Dis. 2014;14:
4 Tedizolid in Skin/Soft Tissue cont.. Results TZD (n=664) LZD (n=669) Success rate at 48-72h 547 (82.4%) 521/653 (79.8%) Success rate at EOT 518 (78.0%) 534 (79.8%) Cellulitis At 48-72h 235/301 (78.1%) 235/307 (76.5%) At EOT (I only) 85/133 (63.9%) 84/135 (62.2%) Major Abscess At 48-72h 139/168 (82.7%) 145/166 (87.4%) At EOT (I only) 72/100 (72.0%) 78/97 (80.4%) Wound/SSI At 48-72h 173/195 (88.7%) 162/196 (82.7%) At EOT (I only) 73/99 (73.7%) 79/103 (76.7%) MRSA (EOT) (II only) 44/53 (83.0%) 44/56 (78.6%) Tedizolid in Skin/Soft Tissue cont.. Adverse Events: Nausea (8.5%), headache (6.3%), diarrhea (4.5%), abscess (4.2%) Hematologic effects seen less frequently with TZD Conclusion: IV/PO TZD x 6 days was non-inferior compared to IV/PO LZD x 10 days in the treatment of ABSSSI Prokocimer. JAMA 2013;309: Moran. Lancet Infect Dis. 2014;14: Prokocimer. JAMA 2013;309: Moran. Lancet Infect Dis. 2014;14: Tedizolid Future Directions? Nosocomial Pneumonia: Ph3, DB, RCT: TZD 200 mg IV q24h x 7 days vs. LZD 600 mg IV q12h x 10 days for Gram-positive HAP/VAP (14 days if concurrent bacteremia) (NCT ) Pediatrics: Ph3, DB, RCT: TZD 200 mg IV/PO q24h x 6 days vs. Iv to PO Vanco/LZD/Clinda/Fluclox/Cefaz/Cepha x 10 days (NCT ) Young & the Restless Are these new whippersnappers better than the tried and true? Ceftaroline Daptomycin Linezolid Telavancin Ceftaroline Cephalosporin antibiotic 600 mg IV q12h Rash, + Coombs test $2400 Ceftaroline Indications Complicated Skin and Skin Structure: CANVAS Corey. Clin Infect Dis. 2010;51: CPT 600 mg IV q12h (n=693) vs. VAN + AZT (1g IV q12h each) (n=685) 91.6% CPT vs. 92.7% VAN + AZT (-1.1% diff, 95% CI -4.2 to 2.0) * +/- *Also active against penicillin- and ceftriaxone-resistant S. niae Community Acquired Pneumonia: FOCUS File. Clin Infect Dis. 2010;51: CPT 600 mg IV q12h (n=621) vs. CTX 1g IV q24h (n=619) 84.3% CPT vs. 77.7% CTX (6.7% diff, 95% CI 1.6 to 11.8) Teflaro Prescribing Information 4
5 Ceftaroline Future Directions? NCT : Non-randomized, open-label study of CPT vs. VAN or DAP for MSSA or MRSA bacteremia CPT dosing: 600 mg IV q8h Daptomycin Cyclic Lipopeptide antibiotic 4 or 6 mg/kg IV q24h CPK, myopathy, eosinophilic nia CPK: creatine phosphokinase $ Cubicin Prescribing Information Daptomycin Indications Skin and Skin Structures: Arbeit. Clin Infect Dis. 2004;38: DAP 4 mg/kg IV q24h (n=446) vs. NAF/VAN (n=456) 83.4% DAP vs. 84.2% NAF/VAN (95% CI -4.0 to 5.6) Bacteremia and Endocarditis: Fowler. NEJM. 2006;355: DAP 6 mg/kg IV q24h (n=124) vs. NAF/VAN + GENT (n=122) 44.2% DAP vs. 41.7% NAF/VAN (2.4% diff, 95% CI 10.2 to 15.1%) Linezolid Oxazolidinone antibiotic 600 mg IV/PO q12h (400 mg IV/PO q12h) Thrombocytopenia, $1400 leukopenia, optic neuritis, (IV) lactic acidosis, serotonin $2700 syndrome (PO) Carries FDA labeled indication for infections Zyvox Prescribing Information Linezolid Indications Complicated Skin and Skin Structures: Weigelt. Antimicrob Agents Chemother. 2005;49: LZD 600 mg IV q12h (n=592) vs. VAN 1g IV q12h (n=588) 92.2% LZD vs. 88.9% VAN (p=0.057) MRSA Pneumonia: ZEPHYR Wunderink. Clin Infect Dis. 2012;54:621-9 LZD 600 mg IV q12h (n=224) vs. VAN 15 mg/kg IV q12h (n=224) Clinical cure: 57.6% LZD vs. 46.6% VAN (95% CI 0.5% to 21.6%, p=0.042) 60 day mortality: 15.7% LZD vs. 17.0% VAN (p=ns) Telavancin Lipoglycopeptide antibiotic 10 mg/kg IV q24h Diarrhea, taste disturbance, foamy urine, nephrotoxicity, QTc prolongation $3100 +/- Vibativ Prescribing Information 5
6 Telavancin Indications Complicated Skin and Skin Structure: ATLAS Stryjewski. Clin Infect Dis. 2008;46: TLV 10 mg/kg IV q24h (n=928) vs. VAN 1g IV Q12h (n=939) 88.3% TLV vs. 87.1% VAN (95% CI for diff, -2.1 to 4.6) ATTAIN Hospital-Acquired, Ventilator-Associated Pneumonia: Rubinstein. Clin Infect Dis. 2011;52:31-40 TLV 10 mg/kg IV q12h (n=749) vs. VAN 1g IV q12h (n=754) 58.9% TLV vs. 59.5% VAN (95% CI for diff, -5.6% to 4.3%) Telavancin Future Directions? Uncomplicated Bacteremia: ASSURE Stryjewski. BMC Infect Dis. 2014;14:289 Phase 2 trial of TLV 10 mg/kg IV q24h (n=29) vs. VAN 1g V q12h/naf 2g IV q6h (n=29) 48% MRSA, 52% MSSA CE: 7/8 (88%) TLV vs. 8/9 (89%) VAN/NAF (95% CI for diff, -35.5% to 31.9%) CE: Clinically evaluable Don t Cry for Me Vancomycin The truth is, we never left you Drug of Choice Safe Effective Cheap In Summary: Drug Profiles Drug Dose Route Renal Adj Hepatic Adj Cost* VAN 15 mg/kg IV q12h IV $600 CPT 600 mg q12h IV $2400 DAL 1000 mg x1, then 500 mg 7 days later IV $4500 DAP 4 or 6 mg/kg q24h IV $3800 LZD 600 mg q12h IV PO $1400 $2700 ORI 1200 mg x1 IV $2900 TLV 10 mg/kg q24h IV $3100 TZD 200 mg q24h IV / PO $1400 ; 6 day course In Summary: Spectrum of Activity Drug VAN CPT +/- DAL +/- DAP LZD ORI TLV +/- TZD In Summary: FDA Approved Indications Drug VAN Skin/Soft Tissue CPT DAL CAP HAP / VAP Bacteremia / Endocarditis Infections caused by susceptible organisms DAP LZD ORI TLV TZD 6
7 Coming Attractions Phase 3 Drug Class MRSA Route Notes Ceftobiprole Cephalosporin IV - ABSSSI, HAP, & CAP - Anti-pseudomonal activity - Approved in Europe for HAP & CAP Delafloxacin Fluoroquinolone IV/PO - ABSSSI & Gonorrhea Iclaprim Omadacycline Dihydrofolate reductase inhibitor Aminomethycycline (tetracycline-like) IV/PO - ABSSSI IV/PO - ABSSSI & CAP Coming Attractions Phase 2 Drug Class MRSA Route Notes BC-3781 Pleuromutilin IV/PO - ABSSSI & CAP Brilacidin Defensin-mimetic IV - ABSSSI Fusidic acid Fusidane PO - ABSSSI - Available outside US for years, different dosing GSK Hydrazinopyrimidine PO - ABSSSI JNJ-Q2 Fluoroquinolone IV/PO - ABSSSI & CAP Linopristin/ Flopristin togrammin PO - ABSSSI & CAP Radezolid Oxazolidinone IV/PO - ABSSSI & CAP TD-1792 Glycopeptidecephalosporin heterodimer IV - ABSSSI Information compiled from Information compiled from In Summary Dalbavancin Tedizolid Oritavancin ABSSSI Pros Convenience Patient compliance Oral option Administration locations Targets resistant organisms Improvements on Cons Cost Reimbursement issues Medication reconciliation Limited indications Subsequent infections Prolonged? Scenario 1 PH is a 76 year old female who came in through the ED for left lower extremity cellulitis and abscess. The abscess was successfully drained and a line was inserted under IR guidance. The patient completed 3 days of vancomycin, before IV access was lost. The team asks you what the patient can be treated with, if they cannot insert another line. What do you recommend? A. Vancomycin B. Dalbavancin C. Tedizolid D. Oritavancin Scenario 2 GR is a 34 year old male with a history of IV drug abuse. He last used 4 days ago and now presents with a right arm cellulitis. GR has frequent episodes of cellulitis and he admits that he never finishes the course of antibiotics prescribed for him. He is also threatening to leave AMA this afternoon. The team asks for treatment recommendations in this patient. What do you recommend? A. Vancomycin B. Dalbavancin C. Tedizolid D. Oritavancin 7
8 Scenario 3 JB is a 47 year old female with diabetes who presents with a wound infection on her left foot. It does not probe to bone. She is slightly hypotensive, so the team admits her to the floor to monitor. They would like to start one of the new antibiotics on her and ask for your recommendation. In speaking to the patient, you uncover that she has an allergy to vancomycin hives. What do you recommend? A. Vancomycin B. Dalbavancin C. Tedizolid D. Oritavancin Scenario 4 OS is a 66 year old male seen in an outpatient clinic for a purulent cellulitis. He receives a dose of oritavancin 1200 mg and is discharged home. Three days later he presents to the ED, complaining of fevers, chills, and feeling lethargic. His cellulitis site looks improved. Laboratory values show a WBC of 14.6 cells/mm 3 and blood cultures are growing GPC in pairs and clusters. The ED pages you asking for drug recommendations. How do you respond? A. The patient already has oritavancin on board, it should cover his current bacteremia. B. Administer another dose of oritavancin to cover the bacteremia. C. Start the patient on vancomycin. D. Start the patient on linezolid, a non-glycopeptide antibiotic. References Choose Your Own Antibiotic/Adventure Gram-Positive Style Monica V. Mahoney, PharmD, BCPS (AQ ID) Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38: Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis. 2005;41:S Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370: Corey GR, Good S, Jiang H, et al. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2014; doi: /cid/ciu778 Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370: Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51: Cubicin Prescribing Information. Cubist Pharmaceuticals, Inc. Lexington, MA Dalvance Prescribing Information. Durata Therapeutics. Chicago, IL Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41:S References cont. File TM, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired nia. Clin Infect Dis. 2010;51: Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355: Moran GJ, Fang E, Corey GR, Das AF, DeAnda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14: Orbactiv Prescribing Information. The Medicines Company. Parsippany, NJ Prokocimer P, DeAnda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections. JAMA 2013;309: Rodvold KA, McConeghy KW. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis. 2014;58:S20-7 Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired nia due to gram-positive pathogens. Clin Infect Dis. 2011;52:31-40 Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, Infect Control Hosp Epidemiol. 2013;34:1-14 References cont. Sivextro Prescribing Information. Cubist Pharmaceuticals, Inc. Lexington, MA Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008;46: Stryjewski ME, Lentnek A, O Riordan W, et al. A randomized phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis. 2014;14:289 Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired nia. Diagn Microbiol Infect Dis. 2008;61: Teflaro Prescribing Information. Forest Laboratories, Inc. St. Louis, MO Tygacil Prescribing Information. Pfizer Inc. New York, NY Vibativ Prescribing Information. Theravance, Inc. San Francisco, CA Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49: Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial nia: a randomized, controlled study. Clin Infect Dis. 2012;54:621-9 Zyvox Prescribing Information. Pfizer Inc. New York, NY
New Antibiotics for MRSA
New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationStaph Cases. Case #1
Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling
More informationSkin and Soft Tissue Infections Emerging Therapies and 5 things to know
2011 MFMER slide-1 Skin and Soft Tissue Infections Emerging Therapies and 5 things to know Aaron Tande, MD Assistant Professor of Medicine October 27, 2017 Division of INFECTIOUS DISEASES 2011 MFMER slide-2
More informationSKIN AND SOFT TISSUE INFECTIONS OCTOBER 3-4, 2015
SKIN AND SOFT TISSUE INFECTIONS OCTOBER 3-4, 2015 Disclosures I have no financial conflicts of interest to disclose or report. Steven Tran, PharmD NEFSHP Fall Meeting 2015 Objectives for Pharmacists Review
More informationAntibiotic Updates: Part I
Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationClass Review: Oxazolidinone Antibiotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAntimicrobials Update
Antimicrobials Update Rosie Amini, PharmD. BCPS Antimicrobial Stewardship Program Coordinator Swedish Medical Center Disclosures: Dr. Amini has no significant financial interest in any of the products
More informationMRSA What Are Our Treatment Options and How Do We Choose the Right One?
MRSA What Are Our Treatment Options and How Do We Choose the Right One? Kristi Traugott, PharmD, BCPS Clinical Pharmacy Specialist Infectious Diseases University Health System San Antonio, TX October 25,
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationCritical impact of antimicrobial resistance
New Antibiotics Kurt B. Stevenson, MD, MPH Professor of Medicine and Epidemiology Division of Infectious Diseases Department of Internal Medicine The Ohio State University College of Medicine Critical
More informationAntimicrobial Therapy
Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the
More informationSIVEXTRO (tedizolid phosphate) oral tablet ZYVOX (linezolid) oral suspension and tablet
ZYVOX (linezolid) oral suspension and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationOne-Hit Wonders: A New Era of Antibiotics?
One-Hit Wonders: A New Era of Antibiotics? Patrick Wieruszewski, PharmD PGY-1 Pharmacy Resident Pharmacy Grand Rounds November 1, 2016 2016 MFMER slide-1 Objectives Identify advantages and disadvantages
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationThe role of new antibiotics in the treatment of severe infections: Safety and efficacy features
The role of new antibiotics in the treatment of severe infections Safety and efficacy features Christian Eckmann Hannover, Germany The role of new antibiotics in the treatment of severe infections: Safety
More informationDiscussion Points. Decisions in Selecting Antibiotics
Antibiotics in Acute Care Fredrick M. Abrahamian, D.O., FACEP, FIDSA Clinical Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical
More informationOptimizing Antibiotic Treatment of Skin and Soft Tissue Infections
Optimizing Antibiotic Treatment of Skin and Soft Tissue Infections 15th Annual Rocky Mountain Hospital Medicine Symposium November 6, 2017 Tim Jenkins, MD Director, Antibiotic Stewardship Program Denver
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationUpdates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Conflict of Interest I, Kaitlin McGinn, have no actual or potential conflict of interest in relation to this program. Kaitlin
More informationUpdates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Kaitlin McGinn, PharmD Assistant Clinical Professor, Critical Care Auburn University, Harrison School of Pharmacy November
More informationAntibacterials. Recent data on linezolid and daptomycin
Antibacterials Recent data on linezolid and daptomycin Patricia Muñoz, MD. Ph.D. (pmunoz@micro.hggm.es) Hospital General Universitario Gregorio Marañón Universidad Complutense de Madrid. 1 GESITRA Reasons
More informationDurata Therapeutics Presents New Comprehensive Review of the Efficacy and Safety Data of Dalbavancin and New In Vitro Findings at IDWeek 2013
October 2, 2013 Durata Therapeutics Presents New Comprehensive Review of the Efficacy and Safety Data of Dalbavancin and New In Vitro Findings at IDWeek 2013 SAN FRANCISCO, Oct. 2, 2013 (GLOBE NEWSWIRE)
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationBest Antimicrobials for Staphylococcus aureus Bacteremia
Best Antimicrobials for Staphylococcus aureus Bacteremia I. Methicillin Susceptible Staph aureus (MSSA) A. In vitro - Anti-Staphylococcal β-lactams (Oxacillin, Nafcillin, Cefazolin) are more active B.
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationMethicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship
Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship Natalie R. Tucker, PharmD Antimicrobial Stewardship Pharmacist Tyson E. Dietrich, PharmD PGY2 Infectious Diseases
More informationDuration of antibiotic therapy:
Duration of antibiotic therapy: How low can you go? Thomas Holland, MD Hilton Head, SC July 2017 Disclosures Consulting: The Medicines Company, Basilea Pharmaceutica Adjudication committee: Achaogen Grant
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationNorthwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
More informationGORILLACILLINS IN THE ICU:
Conflicts of Interest None to declare GORILLACILLINS IN THE ICU: From SPACE and Beyond... Tim T.Y. Lau, PharmD, FCSHP Clinical Pharmacy Specialist in Infectious Diseases Pharmaceutical Sciences, Vancouver
More informationThe Journal of Emergency Medicine, Vol. 44, No. 6, pp. e397 e412, 2013 Copyright Ó 2013 Elsevier Inc. Printed in the USA. Open access under CC BY-NC-ND license. 0736-4679 http://dx.doi.org/10.1016/j.jemermed.2012.11.050
More informationDalbavancin, Oritavancin, and Tedizolid for the Treatment of Skin and Soft Tissue Infections
Dalbavancin, Oritavancin, and Tedizolid for the Treatment of Skin and Soft Tissue Infections Corresponding Author: Robert D. Beckett, PharmD, BCPS* + Director of the Drug Information Center Assistant Professor
More informationAntimicrobial development: Overview and Update. Sumati Nambiar MD MPH Division of Anti-Infective Products FDA
Antimicrobial development: Overview and Update Sumati Nambiar MD MPH Division of Anti-Infective Products FDA American College of Physicians, Washing ton Chapter November 17, 2012 Disclaimer The views expressed
More informationNovel therapies & the role of early switch and early discharge protocols for management of MRSA infections
Novel therapies & the role of early switch and early discharge protocols for management of MRSA infections Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology & Centre for Clinical Pharmacy Louvain
More informationNew Antibiotics & New Insights into Old Antibiotics
New Antibiotics & New Insights into Old Antibiotics Louisiana Chapter of the American Academy of Pediatrics August 18, 2018 Baton Rouge, Louisiana John Bradley MD Rady Children s Hospital San Diego University
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationThe Medical Letter. on Drugs and Therapeutics. Objective Drug Reviews Since Volume 56 August 18, 2014
The Medical Letter on Drugs and Therapeutics Objective Drug Reviews Since 1959 Volume 56 ISSUE ISSUE No. 1433 1449 Volume 56 IN THIS ISSUE Two New Drugs for Skin and Skin Structure Infections...p 73 Important
More informationOptimize Durations of Antimicrobial Therapy
Optimize Durations of Antimicrobial Therapy Evidence & Application Jill Cowper, Pharm.D. Division Infectious Diseases Pharmacist Parallon Supply Chain Solutions Richmond, VA P: 607 221 5101 jill.butterfield@parallon.com
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationInfectious Disease Issues in the Intensive Care Unit
Infectious Disease Issues in the Intensive Care Unit Catherine Liu, M.D. Assistant Clinical Professor Division of Infectious Diseases University of California, San Francisco Overview Emerging antibiotic
More informationInfectious Disease Update 2017
Infectious Disease Update 2017 Greg Moran, MD, FACEP, FIDSA Professor of Clinical Emergency Medicine Geffen School of Medicine at UCLA Dept. of Emergency Medicine and Division of Infectious Diseases Olive
More informationCefazolin vs. Antistaphyloccal Penicillins: The Great Debate
Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Annie Heble, PharmD PGY2 Pediatric Pharmacy Resident Children s Hospital Colorado Microbiology Rounds March 22, 2017 Image Source: Buck cartoons
More informationMRSA ventilatorassociated
MRSA ventilatorassociated pneumonia Jean Chastre, M.D. www.reamedpitie.com Conflicts of interest Consulting or lecture fees: Medimmune/Astrazeneca, Bayer, Pfizer, Arsanis, Cubist/Merck, Basilea, Aridis,
More informationMRSA across roads: new antibiotic options
MRSA across roads: new antibiotic options Javier Garau, MD, PhD University of Barcelona 18th Infection and Sepsis Symposium, BUGS, MUGS AND DRUGS, Porto, 27th February 2013 DISCLOSURES I have accepted
More informationBradley M. Wright 1 and Edward H. Eiland III Introduction
SAGE-Hindawi Access to Research Journal of Pathogens Volume 2011, Article ID 347969, 6 pages doi:10.4061/2011/347969 Clinical Study Retrospective Analysis of Clinical and Cost Outcomes Associated with
More informationCANVAS 1 and 2: Analysis of Clinical Response at Day 3 in Two Phase 3 Trials of
AAC Accepts, published online ahead of print on 6 February 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.05738-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 CANVAS
More informationManaging serious Gram positive infection 2018 Matthew Dryden MD Director of Infection Royal Hampshire County Hospital, Winchester University of
Managing serious Gram positive infection 2018 Matthew Dryden MD Director of Infection Royal Hampshire County Hospital, Winchester University of Southampton matthew.dryden@hhft.nhs.uk Disclosures Consulting
More informationCLINICAL USE OF BETA-LACTAMS
CLINICAL USE OF BETA-LACTAMS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu WHY IS INFECTIOUS DISEASE PHARMACOTHERAPY SO CONFUSING? Microbial
More informationPharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care
Pharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care Jennifer McCann, PharmD, BCCCP State Director of Clinical Pharmacy Services St. Vincent Health Indiana Conflicts of Interest No
More informationDuke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients
Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity
More informationDisclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationAntibiotic Duration for Common Infections
Antibiotic Duration for Common Infections Emily Spivak, MD, MHS Division of Infectious Diseases Medical Director, Antimicrobial Stewardship Program University of Utah Hospitals and Clinics Learning Objectives
More informationAntibiotics and Stewardship: What s New in Pediatrics-Land?
Antibiotics and Stewardship: What s New in Pediatrics-Land? Sean P. Elliott, MD Professor of Pediatrics Associate Chair of Education, Department of Pediatrics University of Arizona College of Medicine
More informationBAD BUGS, MORE DRUGS 10/6/2015 UPDATE ON NEWLY FDA APPROVED ANTIBIOTICS FOR THE TREATMENT OF CELLULITIS PHARMACIST OBJECTIVES
BAD BUGS, MORE DRUGS UPDATE ON NEWLY FDA APPROVED ANTIBIOTICS FOR THE TREATMENT OF CELLULITIS HAYLEY MEYER PGY 1 PHARMACY PRACTICE RESIDENT IOWA CITY VETERANS AFFAIRS HEALTHCARE SYSTEM PHARMACIST OBJECTIVES
More informationLEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES
LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES Goodbye to the Antibiotic Era? Glenn D. Bedsole, MD, FACP Infectious Disease Consultant 1. Be able to list 6 examples of resistant bacteria that present
More informationWhat s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
More informationThe new antistaphylococcal drugs (tigecycline, daptomycin, telavancin, ): is the future (really) shining?
S. aureus: what do we need to know (and to do) in 2007? The new antistaphylococcal drugs (tigecycline, daptomycin, telavancin, ): is the future (really) shining? Françoise Van Bambeke Unité de Pharmacologie
More informationFM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment...
Jillian O Keefe Doctor of Pharmacy Candidate 2016 September 15, 2015 FM - Male, 38YO HPI: Previously healthy male presents to ED febrile (102F) and in moderate distress ~2 weeks after getting a tattoo
More informationZyvox. Zyvox (linezolid) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.20 Subject: Zyvox Page: 1 of 7 Last Review Date: March 18, 2016 Zyvox Description Zyvox (linezolid)
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationNewsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017
Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Fluoroquinolones Newsflash: Fluoroquinolones Don t
More informationMeasurement of Antimicrobial Drug Use. Elizabeth Dodds Ashley, PharmD, MHS, FCCP, BCPS DASON Liaison Pharmacist
Measurement of Antimicrobial Drug Use Elizabeth Dodds Ashley, PharmD, MHS, FCCP, BCPS DASON Liaison Pharmacist Defined Daily Dose Target Audience: Administrators and Epidemiologists Standardized definition
More informationTherapeutic options: what s new in the pipeline?
Therapeutic options: what s new in the pipeline? Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology & Centre for Clinical Pharmacy Louvain Drug Research Institute, Université catholique de Louvain,
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: Oregon Health Plan
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationGetting Smart about Skin Infections and MRSA
Getting Smart about Skin Infections and MRSA Loren G. Miller, M.D., M.P.H. Associate Professor of Medicine David Geffen School of Medicine at UCLA Division of Infectious Diseases Director, Infection Control
More informationAntimicrobial Update. Vicky Dudas, Pharm.D. Associate Clinical Professor of Pharmacy Director, Antimicrobial Management Program UCSF Medical Center
Antimicrobial Update Vicky Dudas, Pharm.D. Associate Clinical Professor of Pharmacy Director, Antimicrobial Management Program UCSF Medical Center Objectives Discuss treatment of acute bacterial rhinosinusitis
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationBAD BUGS, MORE DRUGS 10/6/2015 PHARMACIST OBJECTIVES UPDATE ON NEWLY FDA APPROVED ANTIBIOTICS FOR THE TREATMENT OF CELLULITIS BACKGROUND
BAD BUGS, MORE DRUGS UPDATE ON NEWLY FDA APPROVED ANTIBIOTICS FOR THE TREATMENT OF CELLULITIS HAYLEY MEYER PGY 1 PHARMACY PRACTICE RESIDENT IOWA CITY VETERANS AFFAIRS HEALTHCARE SYSTEM PHARMACIST OBJECTIVES
More informationRole of IV Therapy in Bone and Joint Infection
Role of IV Therapy in Bone and Joint Infection Andrew Seaton ID Consultant, Queen Elizabeth University Hospital Lead Doctor Antimicrobial Management Team, NHS GGC @raseaton66 OPAT The IVnOAT Perspective
More informationAntibiotic Update 2015
Antibiotic Update 2015: Disclosures Antibiotic Update 2015 No Financial Conflicts of Interest Shireesha Dhanireddy, MD 23 April 2015 Current Concepts in Drug Therapy Antibiotic Update 2015: Outline Cystitis
More informationIntra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018
Intra-Abdominal Infections Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Select guidelines Mazuski JE, et al. The Surgical Infection
More informationThe Impact of meca Gene Testing and Infectious Diseases Pharmacists. Intervention on the Time to Optimal Antimicrobial Therapy for ACCEPTED
JCM Accepts, published online ahead of print on 7 May 2008 J. Clin. Microbiol. doi:10.1128/jcm.00801-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationNew Antibiotics & New Insights into Old Antibiotics
New Antibiotics & New Insights into Old Antibiotics Louisiana Chapter of the American Academy of Pediatrics August 18, 2018 Baton Rouge, Louisiana John Bradley MD Rady Children s Hospital San Diego University
More informationPIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS
PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis
More informationSummary of Ceftaroline Fosamil Clinical Trial Studies and Clinical Safety
SUPPLEMENT ARTICLE Summary of Ceftaroline Fosamil Clinical Trial Studies and Clinical Safety Thomas M. File Jr, 1,2 Mark H. Wilcox, 3,4 and Gary E. Stein 5 1 Infectious Disease Section, Northeast Ohio
More informationRESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery
RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,
More informationCEFTAROLINE FOSAMIL (ZINFORO )
Page 1 London New Drugs Group APC/DTC Briefing Document CEFTAROLINE FOSAMIL (ZINFORO ) Contents Summary 1 Background 3 Ceftaroline 4 Clinical efficacy 6 FOCUS 1 and 2 6 CANVAS 1 and 2 9 Health economics
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationTreatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days
Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of
More informationCeftaroline fosamil: A super-cephalosporin?
CURRENT DRUG THERAPY CME CREDIT EDUCATIONAL OBJECTIVE: Readers will understand ceftaroline s place in therapy and optimize its use RIANE J. GHAMRAWI, PharmD, BCPS Clinical Pharmacist Specialist, Adult
More informationAppropriate Antibiotic Prescribing: Making Good Choices for Bad Bugs. Disclosure 4/22/17
Appropriate Antibiotic Prescribing: Making Good Choices for Bad Bugs Elizabeth O. Hand, Pharm.D., BCPS Pediatric Infectious Disease Pharmacist University Health System Clinical Assistant Professor The
More informationEmpiric therapy for severe suspected Staphylococcus aureus infection
Empiric therapy for severe suspected Staphylococcus aureus infection Salman Qureshi, MD McGill University Faculty of Medicine Department of Critical Care Medicine McGill University Health Centre Relevant
More informationLINEE GUIDA: VALORI E LIMITI
Ferrara 28 novembre 2014 LINEE GUIDA: VALORI E LIMITI Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi EVIDENCE BIASED GERIATRIC MEDICINE Older patients with comorbid conditions
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationOriginal Article. Suwanna Trakulsomboon, Ph.D., Visanu Thamlikitkul, M.D.
Original Article Vol. 25 No. 2 In vitro activity of daptomycin against MRSA:Trakulsomboon S & Thamlikitkul V. 57 In Vitro Activity of Daptomycin against Methicillin- Resistant Staphylococcus aureus (MRSA)
More informationS aureus infections: outpatient treatment. Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium
S aureus infections: outpatient treatment Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium Intern Med J. 2005 Feb;36(2):142-3 Intern Med J. 2005 Feb;36(2):142-3 Treatment of
More informationCurrent Medical Research and Opinion. ISSN: (Print) (Online) Journal homepage:
Current Medical Research and Opinion ISSN: 0300-7995 (Print) 1473-4877 (Online) Journal homepage: https://www.tandfonline.com/loi/icmo20 Comparative efficacy of antibiotics for the treatment of acute bacterial
More informationOral antibiotics are not always straight forward
Oral antibiotics are not always straight forward OPAT Regional Workshop 1 st May 2018 Fiona Robb, Antimicrobial Pharmacist NHS Greater Glasgow & Clyde Introduction Describe NHS GGC s Oral vs IV Antibiotics
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationSTAPHYLOCOCCI: KEY AST CHALLENGES
Romney Humphries, PhD D(ABMM) Section Chief, UCLA Clinical Microbiology Los Angeles CA rhumphries@mednet.ucla.edu STAPHYLOCOCCI: KEY AST CHALLENGES THE CHALLENGES detection of penicillin resistance detection
More informationGive the Right Antibiotics in Trauma Mitchell J Daley, PharmD, BCPS
Give the Right Antibiotics in Trauma Mitchell J Daley, PharmD, BCPS Clinical Pharmacy Specialist, Critical Care Dell Seton Medical Center at the University of Texas and Seton Healthcare Family Clinical
More informationTACKLING THE MRSA EPIDEMIC
TACKLING THE MRSA EPIDEMIC Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine MRSA Trend (HA + CA) in US TSN Database USA (1993-2003) % of MRSA among S. aureus
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More informationNEW ANTIBACTERIAL DRUGS. Françoise Van Bambeke, PharmD, PhD
EW ATIBACTERIAL DRUGS Drug pipeline for Gram-positive bacteria Françoise Van Bambeke, PharmD, PhD Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute Université catholique de Louvain,
More information